Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
WJB001 + paclitaxel
- Development stage
- Unknown
- Lead developer
- Wigen Biomedicine Technology
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Intravenous
01
Overview
WJB001 + paclitaxel is a combination therapy consisting of WJB001, a recombinant humanized monoclonal antibody targeting vascular endothelial growth factor (VEGF), and paclitaxel, a taxane-based microtubule stabilizer. WJB001, developed by Wujiang Bio-pharm, is a biosimilar of bevacizumab that acts as an angiogenesis inhibitor by binding to VEGF and preventing its interaction with VEGFR-1 and VEGFR-2, thereby inhibiting new blood vessel formation in tumors. Paclitaxel interferes with the normal function of microtubule breakdown during cell division, leading to cell cycle arrest and apoptosis. This combination is primarily investigated for the treatment of advanced solid tumors, including non-small cell lung cancer (NSCLC), where the anti-angiogenic effects of WJB001 are intended to complement the cytotoxic effects of paclitaxel.
- Other names
- WJB001 + paclitaxelWJB-001 + paclitaxel
02
Targets
TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on WJB001 + paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on WJB001 + paclitaxel.